Physician profile
Deborah Freeman
NPI 1922158617
$5,930.95
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,847 · 2020: $83.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $5,372.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $112.70 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $71.38 | 2019 | |
| Abbvie INC. | $67.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.11 | 2019-2020 | |
| Shire North American Group INC | $45.24 | 2019 | |
| Insulet Corporation | $40.91 | 2019 | |
| Novo Nordisk INC | $35.66 | 2019 | |
| Tandem Diabetes Care, INC. | $30.73 | 2019-2020 | |
| Abbott Laboratories | $30.15 | 2019 | |
| Amgen INC. | $27.86 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $18.12 | 2019 | |
| Ibsa Pharma INC. | $16.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.